Hara, Ryoki
Umebayashi, Hiroaki
Takei, Syuji
Okamoto, Nami
Iwata, Naomi
Yamasaki, Yuichi
Nakagishi, Yasuo
Kizawa, Toshitaka
Kobayashi, Ichiro
Imagawa, Tomoyuki
Kinjo, Noriko
Amano, Norihito
Takahashi, Yoko
Mori, Masaaki
Itoh, Yasuhiko
Yokota, Shumpei
Funding for this research was provided by:
Bristol-Myers Squibb K.K.
Ono Pharmaceutical Co., Ltd. (NA)
Article History
Received: 17 October 2018
Accepted: 11 April 2019
First Online: 30 April 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. An institutional review board or independent ethics committee at each site approved the protocol, consent form, and any other written information provided to patients or their legal representatives.
: Not applicable
: M.M. received research grants from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma, UCB Japan Co., Ltd., CSL Behring, Towa Pharmaceutical Co., Ltd., AbbVie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co. and Nippon Kayaku Co., Ltd.; speaker fees from MSD K.K; and consulting fees from Daiichi Sankyo Co., Ltd. and Taisho Pharmaceutical Co., Ltd. N.A. and Y.T. are employees of Bristol-Myers Squibb K.K. All other authors declare no conflicts of interest associated with this manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.